Drug intelligence / Profile preview

HP-001

Development stage: Phase 2
Lead developer: Shanghai Chaoyang Pharmaceutical
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

HP-001 is a degradable molecular glue drug candidate developed by Shanghai Helioson Pharmaceutical. It functions as an inhibitor of the transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), which are zinc finger proteins involved in the regulation of lymphocyte development and survival. By promoting the degradation of these proteins, HP-001 is designed to disrupt cancer cell growth, particularly in hematologic malignancies such as multiple myeloma and non-Hodgkin's lymphoma. The drug is currently being evaluated in Phase 1 clinical trials for relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma[1][4].

Targets

IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)

Beyond the preview

Go deeper on HP-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP-001.

Explore the full profile